These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 12397645)
1. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Mild G; Bachmann F; Boulay JL; Glatz K; Laffer U; Lowy A; Metzger U; Reuter J; Terracciano L; Herrmann R; Rochlitz C Int J Cancer; 2002 Nov; 102(3):254-7. PubMed ID: 12397645 [TBL] [Abstract][Full Text] [Related]
2. STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer. Buess M; Terracciano L; Reuter J; Ballabeni P; Boulay JL; Laffer U; Metzger U; Herrmann R; Rochlitz C Neoplasia; 2004; 6(6):813-20. PubMed ID: 15720808 [TBL] [Abstract][Full Text] [Related]
3. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C Oncology; 2006; 70(5):366-77. PubMed ID: 17179731 [TBL] [Abstract][Full Text] [Related]
4. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137 [TBL] [Abstract][Full Text] [Related]
5. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Arakawa Y; Tachibana O; Hasegawa M; Miyamori T; Yamashita J; Hayashi Y Acta Neuropathol; 2005 Mar; 109(3):294-8. PubMed ID: 15627206 [TBL] [Abstract][Full Text] [Related]
6. [Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof]. Shen HW; Wu YL; Peng SY Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):744-7. PubMed ID: 12899749 [TBL] [Abstract][Full Text] [Related]
7. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer. Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. Shen HW; Gao SL; Wu YL; Peng SY World J Gastroenterol; 2005 Oct; 11(38):5926-30. PubMed ID: 16273601 [TBL] [Abstract][Full Text] [Related]
9. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Tsuji S; Hosotani R; Yonehara S; Masui T; Tulachan SS; Nakajima S; Kobayashi H; Koizumi M; Toyoda E; Ito D; Kami K; Mori T; Fujimoto K; Doi R; Imamura M Int J Cancer; 2003 Aug; 106(1):17-25. PubMed ID: 12794752 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Bai C; Connolly B; Metzker ML; Hilliard CA; Liu X; Sandig V; Soderman A; Galloway SM; Liu Q; Austin CP; Caskey CT Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1230-5. PubMed ID: 10655513 [TBL] [Abstract][Full Text] [Related]
11. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. Jantscheff P; Terracciano L; Lowy A; Glatz-Krieger K; Grunert F; Micheel B; Brümmer J; Laffer U; Metzger U; Herrmann R; Rochlitz C J Clin Oncol; 2003 Oct; 21(19):3638-46. PubMed ID: 14512395 [TBL] [Abstract][Full Text] [Related]
12. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer. Zong L; Chen P; Wang DX World J Gastroenterol; 2014 Apr; 20(15):4440-5. PubMed ID: 24764685 [TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118 [TBL] [Abstract][Full Text] [Related]
15. SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935 [TBL] [Abstract][Full Text] [Related]
16. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. Gal R; Sadikov E; Sulkes J; Klein B; Koren R Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649 [TBL] [Abstract][Full Text] [Related]
17. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C; Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036 [TBL] [Abstract][Full Text] [Related]